2021年和2022Q1板块总结：器械板块（113家样本公司，含科创板）2021收入2713亿元（+20.1%），归母净利润702亿元（+20.1%），
在2020年高基数下依旧稳健增长，毛利率57%，四费率26%, 净利率26%，盈利能力维持高位。分季度看，2021Q2~Q4医疗器械板块单季度
因高基数增速放缓，22Q1单季度收入1066.4亿元（+55.6%），单季度净利润385.5亿元（+74.3%），由于新冠抗原检测试剂放量而提速明
显，22Q1单季度毛利率62.6%（+2.6pp），单季度四费率19.1%(-3.2pp），单季度净利率36.2%（+4.8pp），盈利能力再创新高。剔除新
冠检测试剂（抗原+核酸）的干扰，22Q1单季度收入492.4亿元（-3.8%）,单季度净利润100.2亿元（-35.9%），因2021Q1高基数以及
2022Q1疫情导致常规业绩承压。

21 年器械板块收入在高基数下实现20%快速增长。2021 年国内医疗秩序显著复苏，病人就诊、医院采购等常规活动逐渐接近疫情前水平，常规业务快速增长；同时部分区域新冠疫情屡有反复，相关耗材、诊断产品持续贡献增量业绩，医疗器械行业在去年高基数的基础上仍然保持较好的增速。2021 年医疗器械上市公司收入增长20.76%，扣非净利润增长17.01%；利润增速略低于收入增速，主要系部分新冠相关业务价格下降所致。

体外诊断是指在体外通过对人体体液、细胞和组织等样本进行检测而获取临床诊断信息，进而判断疾病或集体功能的诊断方法。体外诊断在医疗领域被誉为“医生的眼睛”，是现代检验医学的重要构成部分。面对新冠疫情的大考，防护物资、诊疗设备及时扩能扩产，诊断试剂、治疗药物、新冠病毒疫苗应急研发和产业化成效突出，多条技术路线的新冠病毒疫苗顺利实现产业化，并且在短时间内形成了全链条质量安全管控能力，有效满足国内接种需求，为全球抗疫做出积极贡献。

The manufacturing of pharmaceutical products requires high standards to ensure the strength of the active ingredients, purity, and quality of the final products. These standards ensure safe and efficient finished products for patients. Small changes in any of these factors can alter the overall composition and may have serious side effects. Thus, the checks and the controls which are applied need to be more stringent than the food industry.

The global advanced dermatology drug delivery devices market is driven by factors such as the global efforts in increasing the adoption of connected devices, increasing number of business synergies with pharmaceutical companies, novel technologies in drug delivery, and the growing focus on prescription/medication adherence. Manufacturers are more focused on producing devices that offer enhanced patient experience through real-time monitoring and data sharing. The succeeding figure indicates the impact analysis for the different market growth promoting and restraining factors during the forecast period 2021-2030.

New trends in elevators and escalators, such as smart lifts, traction elevators, and pneumatic elevators are creating value grab opportunities for manufacturers. Traction lifts are found to travel faster than hydraulic lifts, and can be used in both high-rise and mid-rise buildings. Hence, companies in the elevator & escalator market are pushing the sales of traction elevators in high-rise buildings of China, owing to high population density. Manufacturers in the elevator & escalator market are targeting pneumatic lifts for places where there is a limited passenger footfall. These lifts are being designed in wheelchair accessiblemode.